Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/OrbiMed Advisors/Activity

OrbiMed Advisors Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Portfolio company RayThera agreed to be acquired by Biogen for up to $1B.

RayThera

RayTheraOrbiMed Advisors

globenewswire.comJUN 17, 2026

orbimed.com

JUN 17, 2026

Investment

Led Accro Bioscience's $50M Series C to advance its immune-mediated disease pipeline.

Accro Bioscience

Accro Bioscience OrbiMed Advisors

prnewswire.comMAY 18, 2026

MAY 18, 2026

Exit

Portfolio company PathAI entered a definitive merger agreement to be acquired by Roche for $750M upfront plus up to $300M in milestones.

PathAI

PathAI OrbiMed Advisors

globenewswire.comMAY 7, 2026

MAY 7, 2026

Exit

Portfolio company Perfuse Therapeutics agreed to be acquired by Bayer for up to $2.45B.

Perfuse Therapeutics

Perfuse TherapeuticsOrbiMed Advisors

bayer.comMAY 6, 2026

MAY 6, 2026

4 investments· MAR 2026 – MAY 2026Show all

Investment

Led Windward Bio's upsized $165M crossover financing to advance long-acting immunology therapies.

Windward Bio

Windward Bio OrbiMed Advisors

globenewswire.comMAY 4, 2026

MAY 4, 2026

Investment

Led $50M financing for Nucleus RadioPharma to expand radiopharmaceutical manufacturing capacity.

Nucleus RadioPharma

Nucleus RadioPharma OrbiMed Advisors

tcbmag.comAPR 21, 2026

APR 21, 2026

Investment

Participated in Sidewinder Therapeutics' $137M Series B financing to advance next-generation bispecific ADCs for cancer.

Sidewinder Therapeutics

Sidewinder Therapeutics OrbiMed Advisors

sidewinderbio.comAPR 8, 2026

APR 8, 2026

Investment

Co-led $39.5M financing for Congruence Therapeutics to advance small molecule correctors into clinical trials.

Congruence Therapeutics

Congruence Therapeutics OrbiMed Advisors

prnewswire.comMAR 19, 2026

MAR 19, 2026

OrbiMed Advisors | Activity | F4